CEO of the Company, Dr.
Dunehoo began the interview by asking about the Company s background and current projects.
By using known therapies, we believe we can develop new drugs more quickly and at reduced costs, while expanding our product pipeline across many indications, continued
We chemically modify a drug, in this case oxycodone, to make it inactive unless swallowed, said
With MPAR, Multi-Pill Abuse Resistance, this takes the protection one step further, continued
We believe TAAP and MPAR make opioids safer, said
When do you anticipate Phase III trials and ultimately the potential commercialization for PF614 , asked Dunehoo. Over the last 18 months we have been working diligently to complete all of the work we need to get to Phase III, said
The conversation then turned to the Company s strategic partnership with
To close the interview,
Investors Hangout is a proud sponsor of Stock Day, and Stock Day Media encourages listeners to visit the company s message board at https://investorshangout.com/
About
Forward-Looking Statements
Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as may, intends, can, might, will, expect, plan, possible, believe and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce s management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce s business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce s product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising and Ensysce s and its partners ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce s most recent quarterly report on Form 10-Q and current reports on Form 8-K, which are available, free of charge, at the
Contact:
Tel: (858) 263-4196
Tel: 203-741-8811
Email: ENSC@mzgroup.us
About The Stock Day Podcast
Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.
(C) 2023 Electronic News Publishing, source